The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
04 2019
Historique:
received: 25 05 2018
revised: 17 10 2018
accepted: 01 11 2018
pubmed: 23 2 2019
medline: 9 6 2020
entrez: 23 2 2019
Statut: ppublish

Résumé

Efforts to quantify the global burden of enteric fever are valuable for understanding the health lost and the large-scale spatial distribution of the disease. We present the estimates of typhoid and paratyphoid fever burden from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, and the approach taken to produce them. For this systematic analysis we broke down the relative contributions of typhoid and paratyphoid fevers by country, year, and age, and analysed trends in incidence and mortality. We modelled the combined incidence of typhoid and paratyphoid fevers and split these total cases proportionally between typhoid and paratyphoid fevers using aetiological proportion models. We estimated deaths using vital registration data for countries with sufficiently high data completeness and using a natural history approach for other locations. We also estimated disability-adjusted life-years (DALYs) for typhoid and paratyphoid fevers. Globally, 14·3 million (95% uncertainty interval [UI] 12·5-16·3) cases of typhoid and paratyphoid fevers occurred in 2017, a 44·6% (42·2-47·0) decline from 25·9 million (22·0-29·9) in 1990. Age-standardised incidence rates declined by 54·9% (53·4-56·5), from 439·2 (376·7-507·7) per 100 000 person-years in 1990, to 197·8 (172·0-226·2) per 100 000 person-years in 2017. In 2017, Salmonella enterica serotype Typhi caused 76·3% (71·8-80·5) of cases of enteric fever. We estimated a global case fatality of 0·95% (0·54-1·53) in 2017, with higher case fatality estimates among children and older adults, and among those living in lower-income countries. We therefore estimated 135·9 thousand (76·9-218·9) deaths from typhoid and paratyphoid fever globally in 2017, a 41·0% (33·6-48·3) decline from 230·5 thousand (131·2-372·6) in 1990. Overall, typhoid and paratyphoid fevers were responsible for 9·8 million (5·6-15·8) DALYs in 2017, down 43·0% (35·5-50·6) from 17·2 million (9·9-27·8) DALYs in 1990. Despite notable progress, typhoid and paratyphoid fevers remain major causes of disability and death, with billions of people likely to be exposed to the pathogens. Although improvements in water and sanitation remain essential, increased vaccine use (including with typhoid conjugate vaccines that are effective in infants and young children and protective for longer periods) and improved data and surveillance to inform vaccine rollout are likely to drive the greatest improvements in the global burden of the disease. Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
Efforts to quantify the global burden of enteric fever are valuable for understanding the health lost and the large-scale spatial distribution of the disease. We present the estimates of typhoid and paratyphoid fever burden from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, and the approach taken to produce them.
METHODS
For this systematic analysis we broke down the relative contributions of typhoid and paratyphoid fevers by country, year, and age, and analysed trends in incidence and mortality. We modelled the combined incidence of typhoid and paratyphoid fevers and split these total cases proportionally between typhoid and paratyphoid fevers using aetiological proportion models. We estimated deaths using vital registration data for countries with sufficiently high data completeness and using a natural history approach for other locations. We also estimated disability-adjusted life-years (DALYs) for typhoid and paratyphoid fevers.
FINDINGS
Globally, 14·3 million (95% uncertainty interval [UI] 12·5-16·3) cases of typhoid and paratyphoid fevers occurred in 2017, a 44·6% (42·2-47·0) decline from 25·9 million (22·0-29·9) in 1990. Age-standardised incidence rates declined by 54·9% (53·4-56·5), from 439·2 (376·7-507·7) per 100 000 person-years in 1990, to 197·8 (172·0-226·2) per 100 000 person-years in 2017. In 2017, Salmonella enterica serotype Typhi caused 76·3% (71·8-80·5) of cases of enteric fever. We estimated a global case fatality of 0·95% (0·54-1·53) in 2017, with higher case fatality estimates among children and older adults, and among those living in lower-income countries. We therefore estimated 135·9 thousand (76·9-218·9) deaths from typhoid and paratyphoid fever globally in 2017, a 41·0% (33·6-48·3) decline from 230·5 thousand (131·2-372·6) in 1990. Overall, typhoid and paratyphoid fevers were responsible for 9·8 million (5·6-15·8) DALYs in 2017, down 43·0% (35·5-50·6) from 17·2 million (9·9-27·8) DALYs in 1990.
INTERPRETATION
Despite notable progress, typhoid and paratyphoid fevers remain major causes of disability and death, with billions of people likely to be exposed to the pathogens. Although improvements in water and sanitation remain essential, increased vaccine use (including with typhoid conjugate vaccines that are effective in infants and young children and protective for longer periods) and improved data and surveillance to inform vaccine rollout are likely to drive the greatest improvements in the global burden of the disease.
FUNDING
Bill & Melinda Gates Foundation.

Identifiants

pubmed: 30792131
pii: S1473-3099(18)30685-6
doi: 10.1016/S1473-3099(18)30685-6
pmc: PMC6437314
pii:
doi:

Substances chimiques

Typhoid-Paratyphoid Vaccines 0

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

369-381

Investigateurs

Jeffrey D Stanaway (JD)
Robert C Reiner (RC)
Brigette F Blacker (BF)
Ellen M Goldberg (EM)
Ibrahim A Khalil (IA)
Christopher E Troeger (CE)
Jason R Andrews (JR)
Zulfiqar A Bhutta (ZA)
John A Crump (JA)
Justin Im (J)
Florian Marks (F)
Eric Mintz (E)
Se Eun Park (SE)
Anita K M Zaidi (AKM)
Zegeye Abebe (Z)
Ayenew Negesse Abejie (AN)
Isaac Akinkunmi Adedeji (IA)
Beriwan Abdulqadir Ali (BA)
Azmeraw T Amare (AT)
Hagos Tasew Atalay (HT)
Euripide F G A Avokpaho (EFGA)
Umar Bacha (U)
Aleksandra Barac (A)
Neeraj Bedi (N)
Adugnaw Berhane (A)
Annie J Browne (AJ)
Jesus L Chirinos (JL)
Abdulaal Chitheer (A)
Christiane Dolecek (C)
Maysaa El Sayed Zaki (M)
Babak Eshrati (B)
Kyle J Foreman (KJ)
Abdella Gemechu (A)
Rahul Gupta (R)
Gessessew Bugssa Hailu (GB)
Andualem Henok (A)
Desalegn Tsegaw Hibstu (DT)
Chi Linh Hoang (CL)
Olayinka Stephen Ilesanmi (OS)
Veena J Iyer (VJ)
Amaha Kahsay (A)
Amir Kasaeian (A)
Tesfaye Dessale Kassa (TD)
Ejaz Ahmad Khan (EA)
Young-Ho Khang (YH)
Hassan Magdy Abd El Razek (H)
Mulugeta Melku (M)
Desalegn Tadese Mengistu (DT)
Karzan Abdulmuhsin Mohammad (KA)
Shafiu Mohammed (S)
Ali H Mokdad (AH)
Jean B Nachega (JB)
Aliya Naheed (A)
Cuong Tat Nguyen (CT)
Huong Lan Thi Nguyen (HLT)
Long Hoang Nguyen (LH)
Nam Ba Nguyen (NB)
Trang Huyen Nguyen (TH)
Yirga Legesse Nirayo (YL)
Tikki Pangestu (T)
George C Patton (GC)
Mostafa Qorbani (M)
Rajesh Kumar Rai (RK)
Saleem M Rana (SM)
Chhabi Lal Ranabhat (CL)
Kedir Teji Roba (KT)
Nicholas L S Roberts (NLS)
Salvatore Rubino (S)
Saeid Safiri (S)
Benn Sartorius (B)
Monika Sawhney (M)
Mekonnen Sisay Shiferaw (MS)
David L Smith (DL)
Bryan L Sykes (BL)
Bach Xuan Tran (BX)
Tung Thanh Tran (TT)
Kingsley Nnanna Ukwaja (KN)
Giang Thu Vu (GT)
Linh Gia Vu (LG)
Fitsum Weldegebreal (F)
Melaku Kindie Yenit (MK)
Christopher J L Murray (CJL)
Simon I Hay (SI)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Bull World Health Organ. 2004 May;82(5):346-53
pubmed: 15298225
J Health Popul Nutr. 2004 Sep;22(3):304-10
pubmed: 15609783
Arch Intern Med (Chic). 1946 Dec;78(6):629-61
pubmed: 20278487
Trop Med Int Health. 2011 Mar;16(3):314-23
pubmed: 21223462
J Glob Health. 2012 Jun;2(1):010401
pubmed: 23198130
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
PLoS Negl Trop Dis. 2013;7(1):e1998
pubmed: 23359825
Aliment Pharmacol Ther. 2014 Apr;39(8):745-50
pubmed: 24612190
Lancet Glob Health. 2014 Oct;2(10):e570-80
pubmed: 25304633
J Health Popul Nutr. 2014 Sep;32(3):377-85
pubmed: 25395900
Lancet. 2015 Nov 28;386(10009):2145-91
pubmed: 26321261
J Glob Health. 2015 Dec;5(2):020407
pubmed: 26649174
Lancet. 2016 Oct 8;388(10053):1603-1658
pubmed: 27733283
PLoS Negl Trop Dis. 2017 Feb 27;11(2):e0005376
pubmed: 28241011
Lancet Glob Health. 2017 Oct;5(10):e969
pubmed: 28911760
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
Lancet. 2017 Dec 2;390(10111):2472-2480
pubmed: 28965718
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Am J Trop Med Hyg. 1986 Jul;35(4):836-9
pubmed: 3089041
Am J Med. 1985 Sep;79(3):370-2
pubmed: 3898837
Lancet. 1975 May 31;1(7918):1211-3
pubmed: 48834
J Clin Microbiol. 1978 Feb;7(2):122-6
pubmed: 632343
Arch Dis Child. 1996 Sep;75(3):214-7
pubmed: 8976660

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH